Antibiotics developer Cempra Pharmaceuticals is one of three healthcare companies expected to go public this week. A total of eight initial public offerings are expected this week, according to Renaissance Capital, a Greenwich, Connecticut research firm specializing in initial public offerings. Besides Chapel Hill, North Carolina-based Cempra’s planned $86 million IPO, the other healthcare-related IPOs […]
The initial public offering Cempra Pharmaceuticals plans now has a price. The Chapel Hill, North Carolina drug development company, which has two clinical-stage antibacterial compounds targeting drug-resistant bacteria, expects to sell 6 million shares for between $11 and $13 per share, raising up to $78 million before fees and expenses, according to an updated registration […]
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.
Drug development company Cempra Pharmaceuticals plans to raise $86.2 million in an initial public offering to pay for late-stage clinical trials on a pair of novel antibiotic compounds targeting drug-resistant bacteria. The IPO filing comes a month after Chapel Hill, North Carolina-based Cempra announced positive phase 2 results for antibiotic candidate CEM-101, also called Solithromycin, […]
Cempra Pharmaceuticals‘ bacterial pneumonia drug candidate was demonstrated to be just as effective as a currently available antibiotic and more important, it posed less risk of causing adverse reactions. In announcing phase 2 clinical trial results for solithromycin today, Chapel Hill, North Carolina biotechnology company Cempra said the efficacy of its drug candidate was comparable […]
Cempra Pharmaceuticals, which is developing novel antibiotics targeting drug-resistant bacteria, has raised $5 million in financing, according to securities filings. The Chapel Hill, North Carolina-based company has two clinical stage antibacterial compounds; one of which is being developed to fight nasty skin infections, including MRSA. That compound, called TAKSTA, is set to enter phase 3 […]
The growing prevalence of drug-resistant bacteria means a rise in so-called superbugs with no antibiotics to treat them. Cempra Pharmaceuticals aims to bring new antibacterial weapons to that fight. The Chapel Hill, North Carolina-based pharmaceutical company has two clinical-stage drug candidates, including one for MRSA infections, that would each address the growing problem of antimicrobial […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.